** charts after earnings **
AbbVie beats by $0.05, reports revs in-line; raises FY15 EPS slightly; guides FY16 EPS in-line; sees $37 bln in sales in 2020 with double digit EPS CAGR (ABBV) :
Reports Q3 (Sep) earnings of $1.13 per share, excluding non-recurring items, $0.05 better than the Capital IQ Consensus of $1.08; revenues rose 18.4% year/year to $5.94 bln vs the $5.89 bln Capital IQ Consensus.
- On an operational basis, sales increased 26.2 percent, excluding a 7.8 percent unfavorable impact from foreign exchange rate fluctuations. Third-quarter sales growth was driven by the continued strength of HUMIRA and other promoted products.
- Global HUMIRA sales increased 19.6 percent on an operational basis, or 12.1 percent including the impact of foreign exchange rate fluctuations. Strong U.S. HUMIRA growth of 30.4 percent was driven by continued momentum across all three major market categories, rheumatology, dermatology and gastroenterology.
No comments:
Post a Comment